Clinical Research Directory

Inclusion Criteria: 1. Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent. 2. Men or women aged more than or equal to (≥) 18 years. 3. At least one extra-cranial measurable lesion according to RECIST 1.1. 4. Histologically or cytologically diagnosed as ES-SCLC. 5. Adequate organ function. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1. 7. Life expectancy \>= 12 weeks. 8. Men or women should be using adequate contraceptive measures throughout the study. 9. Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk. Exclusion Criteria: 1. Uncontrolled pleural effusion or peritoneal effusion. 2. Adverse reactions caused by previous treatments. 3. History of other primary solid tumors. 4. Severe, uncontrolled or active cardiovascular or cerebrovascular diseases. 5. Severe or uncontrolled diabetes or hypertension. 6. Clinically significant hemorrhage symptoms or significant hemorrhagic tendency. 7. History of severe arterial-venous thrombosis within 3 months prior to the first administration. 8. History of severe infection within 4 weeks prior to the first administration. 9. Active autoimmune diseases or active infectious diseases. 10. History of severe neurological or mental disorders. 11. Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child-Pugh class B cirrhosis. 12. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period. 13. Any condition that probably endangers the safety of the participants or interferes with the study assessment.